The company, which is 80% owned by Bermuda-based privately-held Roivant Sciences, is developing a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia.

Its vision is to become the leading company focused on the treatment of dementia by broadly addressing multiple forms of this condition through developing innovative new medicines for patients.

In April 2017, Axovant announced the appointment of David Hung as its new chief executive. Dr Hung is founder and former chief executive of Medivation, an oncology-focused biopharma bought by US pharma giant Pfizer for $14 billion in 2016.